Category Business

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030…

Read MoreAstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata

FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age…

Read MoreFDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata

WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change

WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change WHO and international advocacy organization Global Citizen today signed a memorandum of understanding to collaborate on joint global advocacy initiatives aimed…

Read MoreWHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’…

Read MoreBayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology…

Read MoreBayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities

Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has expanded its integrated development, manufacturing and supply solution,…

Read MoreCatalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of…

Read MoreAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023